anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The Randomized Evaluation of Patients with Stable Angina Comparing Utilization of Diagnostic Examinations (RESCUE) is a multi-center randomized, controlled trial responding to the need for comparative analysis of these imaging technologies and the role of OMT in clinical care. A total of 4300 patients will be randomized to CCTA or SPECT MPI/ICA for diagnostic assessment of angina at up to 80 institutions internationally. This study builds on the results of the COURAGE trial by comparing CCTA and SPECT MPI/ICA integrated into a care paradigm featuring initial treatment with OMT for patients diagnosed using computer-aided diagnosis (CAD) without significant disease in the left main coronary artery. Participants will be followed for a composite endpoint of MACE and cross-over to revascularization over a follow-up period up to two years (two to six time points depending on diagnostic results and time of enrollment into the trial). The primary endpoint of the study is a combined endpoint of occurrence of MACE and revascularization. We will calculate differences in the combined MACE/revascularization endpoint between the CCTA and SPECT MPI/ICA arms. Participant outcomes will be assessed by age, gender, comorbidity, and angina classification class at presentation. Several comparative-effectiveness analyses will be performed. We hypothesize that the CCTA arm will be associated with no increase in MACE or revascularization, decreased cost, reduced risks (e.g., less radiation exposure), additional insights into or alternate explanations of chest pain, and increased cost-effectiveness in comparison with SPECT MPI/ICA. Findings are expected to result in validation of an evolving new standard of care for patients with stable angina that takes advantage of CCTA and OMT to more cost-effectively drive appropriate care while reducing the need for invasive diagnosis and increased radiation exposure with SPECT MPI/ICA.
PURPOSE: A composition containing Magnoliae Flos active compounds is provided to suppress bone resorption with less toxicity. CONSTITUTION: A pharmaceutical composition for preventing and treating bone diseases containsMagnoliae Flos active compounds of chemical formula 1 as an active ingredient. The compound is isolated from Magnoliae Flos extract. The composition is administered in dose of 0.01-500 mg/kg. The bone diseases are osteoporosis, osteomalacia, ricket, osteitis fibrosa, aplasia bone disease, or metabolic diseases. A health functional food for preventing and relieving bone diseases contains the compound of chemical formula 1 as an active ingredient.
BACKGROUND: There is an inconsistency in the way pharmaceutical research is financed. While pull mechanisms are predominantly used to incentivize later-stage pharmaceutical research for products with demand in the Global North, so-called neglected diseases are chiefly financed by push funding. This discrepancy has so far been ignored in the academic debate, and any compelling explanation for why we draw the line between push and pull at poor people is lacking.
MAIN BODY: Clinical development of new pharmaceuticals is chiefly financed by free market pull mechanisms. Even in cases where markets fail to deliver adequate incentives, demand enhancement mechanisms are used to replicate pull funding artificially, for example, with subscription models for antibiotics. Push funding in clinical research is almost always used when the poverty of patients means that markets fail to create sufficient demand. The general question of whether push or pull generally is the more efficient way to conduct pharmaceutical research arises.
CONCLUSIONS: If the state is efficient in directing limited budgets for pharmaceutical research, push funding should be expanded to global diseases. If private industry is the more efficient actor, there would be enormous value in experimenting more aggressively with different approaches to enhance market demand artificially for neglected diseases.
Breast cancer is one of the most common malignant tumor in women. About 69.75% of breast cancer women patients in China are over 45 years old. Chemotherapy is one of the important treatments for breast cancer, but it brings a series of adverse effects, especially increasing the risk of hyperlipidemia, cardiovascular disease and osteoporosis in postmenopausal women. It is a multicenter prospective observational study. The postmenopausal breast cancer women patients who are planning adjuvant or neoadjuvant chemotherapy are enrolled in the study after signing the informed consent form and passing the screening. We collect the basic information, medical history, chemotherapy-related adverse reactions, and the results of blood lipid and bone density test before, during and after chemotherapy. The purpose of the study is to investigate the risk factors for hyperlipidemia, cardiovascular disease, and osteoporosis in postmenopausal breast cancer patients before and after chemotherapy, and to assess the risk of future arteriosclerotic cardiovascular disease and osteoporotic fractures in this population.In addition, the collected information of the subjects are analyzed to provide suggestions for the relevant prevention strategy.
Stroke is the second most frequent cause of death and cognitive deficits including dementia occur frequently following a stroke. The frequency of cognitive disturbances has been reported up to 30% and thus occurs three times more frequent than recurrent stroke (10%). Major attempts have been made to prevent the occurrence of new strokes by means of effective strategies including preventive drugs. In contrast, hardly any studies have been performed addressing the prevention of deteriorating cognitive function following a stroke. In spite of this high prevalence therapeutic possibilities are extremely limited. It must be expected that cognitive deficits become even a more frequent disability following stroke. This is caused by the increased aging of the population leading to further increase of incidence, furthermore that more people survive their acute stroke due to increased possibilities of acute treatment, and that frequent risk factors (e.g. hypertension, diabetes) are increasingly controlled, thus leading to less severe strokes with less severe and permanent motor deficits, but an increase of potentially disabling cognitive disturbances. The aim of this randomized controlled study is to test an intensive multiple intervention therapy for the first time in stroke and to add life style modifications targeting modifiable risk factors for cognitive deterioration.

It is hypothesized that the risk of post-stroke cognitive decline can be significantly reduced compared to a control group with standard care when using polyintervention. These interventions will focus on nutrition, exercise, cognitive and social activity and monitoring and management of metabolic and vascular risk factors. Regular contacts with the subjects shall increase motivation and adherence to the study protocol.
Participants will receive increasing doses of NNC0194-0499. The treatment period from first treatment (Day 1) to end of the treatment (Day 85) will be 12 weeks.
PURPOSE: A vasodilator agent for the prevention and treatment of vascular disease containing, as an effective ingredient, a coumarin derivative such as decursin or decursinol angelate is provided. The coumarin derivative separated from Angelica gigas Nakai has vasodilating capacity. It can be used as a therapeutic agent for treatment of hypertension, arteriosclerosis, cerebral infarction, myocardial infarction, peripheral circulatory disturbance or ischemic brain disease. CONSTITUTION: The vasodilator agent for the prevention and treatment of vascular disease contains a coumarin derivative represented by the formula(1) and diluents or excipients. The coumarin derivative contains decursin represented by the formula(2) or decursinol angelate represented by the formula(3). In formula, R1 and R2 are each H or methyl. The diluents are selected from the group consisting of fillers, bulking agents, binding agents, swelling agents, disintegrating agents and surfactants.
PROBLEM TO BE SOLVED: To obtain the subject medicine capable of suppressing melanogenesis by containing guaiol as an active ingredient. SOLUTION: This suppressant contains guaiol as an active ingredient. This preparation for external use for skin is obtained by containing the suppressant for melanogenesis in an amount of 0.01-10wt.% expressed in terms of guaiol. The suppressor for melanogenesis and the preparation for external use for skin are effective in preventing and improving pigmentation, stain, freckle, etc., after sun burn. Guaiol is one kind of sesquiterpene alcohol contained in plants of the families Zygophyllaceae and Cupressaceae and is obtained by extraction from the plants or synthesis. The preparation for external use for skin can be prepared in a dosage form of a solution, oitment, cream, milky lotion, pack, aqueous gel, oily gel, bathing agent, etc., and can be formulated as a finishing cosmetic of foundation, control color, etc.  The preparation for external use for skin can safely be used, because the preparation has no adverse influence on skin.
Additional reductions in blood pressure may occur when epoprostenol is administered with diuretics, antihypertensive agents, or other vasodilators. When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for epoprostenol to increase the risk of bleeding. However, patients receiving infusions of epoprostenol in clinical trials were maintained on anticoagulants without evidence of increased bleeding. In clinical trials, epoprostenol was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen. 

In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with epoprostenol was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87. The change in furosemide clearance value is not likely to be clinically significant. However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with epoprostenol, which may be clinically significant in patients prone to digoxin toxicity.
Surgery for cancer of the esophagus or gastro-esophageal junction can be performed with a variety of minimally invasive and open approaches. The left thoracoabdominal esophagectomy (LTE) is an open technique that gives an opportunity to operate in the chest and abdomen with excellent exposure of the gastro-esophageal junction through a single incision, and there is currently no equivalent minimally invasive technique available. The aim of this multi-institutional review was to study a large contemporary international study cohort of patients treated with LTE. An international multicenter cohort study was performed including all patients treated with LTE at six high-volume centers for gastro-esophageal cancer surgery between 2012 and 2022. Patient data were prospectively collected in each participating centers' institutional database. Information about patient, tumor, and treatment details were collected. The study cohort included a total of 793 patients treated with LTE during the study period. The most frequently observed complications were pneumonia in 185/727 (25.5%) patients and atrial fibrillation in 91/727 (12.5%). Anastomotic leak occurred in 35/727 (4.8%) patients; no patient suffered from conduit necrosis. Thirty-day mortality occurred in 15/785 (1.9%) patients and 90-day mortality in 39/785 (5.0%) patients. Factors with statistically significant association with survival were American Society for Anesthesiologists-score, tumor location, tumor stage, and tumor free resection margins. Neoadjuvant therapy was not associated with increased survival compared to surgery alone but neoadjuvant chemoradiotherapy compared to neoadjuvant chemotherapy showed statistically significant improved survival with hazard ratio 0.60 (95% confidence intervals:0.44-0.80, P = 0.001) in a multivariable adjusted model. This study demonstrates that LTE can be applied in selected patients with results that are comparable to other large studies of open and minimally invasive surgery for esophageal or gastro-esophageal cancer at high-volume centers.
IVM (in vitro maturation) has been proved to be a more friendly treatment protocol for PCOS (polycystic ovary syndrome) patients compared with conventional controlled ovarian stimulation, with less complications (especially ovarian hyperstimulation syndrome), shorter treatment duration, lower cost, and acceptable pregnancy outcomes. CAPA (capacitation) IVM without hCG (human chorionic gonadotropin) priming, has routinely been used at My Duc hospital for nearly 3 years to replace hCG-IVM (with hCG priming) because of absolutely synchronized oocyte maturation stage and better embryo results and better pregnancy outcomes. However, with CAPA IVM, embryos are freezed-only and will be transferred in the next cycles. This process will increase the cost of freezing and thawing embryos, and increase the treatment duration, which complicates the IVM procedure and turns IVM into an unfriendly protocol to PCOS patients. Therefore, our group conducts this study to find out the effectiveness of fresh transfer protocol after CAPA IVM compared with freezing-only CAPA IVM protocol. The fresh transfer protocol for CAPA IVM is applied from previous hCG IVM protocol, with the use of hCG and exogenous estradiol and progesterone, but at different timings.
Segmental Stabilisation Training (SST) a programme initially conceived by Carolyn Richardson and her team, serves as a specialised approach tailored to alleviate mechanical low back pain. Built upon decades of rigorous research, this exercise model rests upon the foundational principles of core stability. SST is unique due to its singular focus on addressing the root cause of low back pain, thereby presenting a promising avenue for averting the frequent relapses characteristic of this condition. Many fitness regimens that emphasize core stability incorporate the Abdominal Drawing-in manoeuver. However, the efficacy of this technique often remains unrealized due to a lack of awareness regarding its correct execution. It is imperative to note that the true benefits of the Abdominal Drawing-in manoeuver manifest only when performed accurately, ensuring the activation of deep core muscles and, in turn, preventing the recurrence of low back pain. The SST programme offers clear and precise guidance, enabling both clinicians and patients to acquire the requisite skills for its correct implementation. This minireview highlights the significance of SST in low back pain management and also elucidates the crucial role of precise technique execution.
The invention provides a preparation method of a double-pH-sensitive poly (2-alkyl-2-oxazoline) -hydrophobic chain-antitumor drug/anti-transfer drug conjugate, a mixed micelle composition and application thereof. The acid-sensitive chemical bond is taken as a connecting arm to couple the poly (2-alkyl-2-oxazoline) -hydrophobic chain with the anti-tumor drug and the anti-transfer drug. The conjugate disclosed by the invention can respond to an acidic environment in a cell to quickly release a drug, and can be self-assembled in an aqueous environment to form a dual pH-sensitive conjugate mixed micelle. The conjugate mixed micelle can avoid the premature release of the drug in systemic circulation, increase the accumulation of the drug in tumor sites and reduce toxic and side effects. In addition, the anti-tumor drug and the anti-metastasis drug in the conjugate mixed micelle have the effects of synergistic anti-tumor growth and anti-metastasis. The conjugate mixed micelle has potential application in the aspects of drug targeted delivery, controlled release, drug toxic and side effect reduction, synergistic antitumor and antitumor metastasis.
The invention describes the method allowing for efficient predictive ranking of clinical efficiencies of the existing targeted medicinal products for individual patient with proliferative or oncology disease. The method makes it possible to use a wide range of experimental data received from the patients' pathological tissue samples and relevant control samples: information on gene mutations, transcription factor binding profile, protein (considering harmonization), mRNA (considering harmonization) and microRNA expression strength. The method also uses information on molecular targets of the medicinal products. This method can be automated to prevent potential errors associated with manual calculation and makes it possible to consider patient-specific changes in hundreds and thousands molecular pathways which include tens and hundreds of gene products. This method also considers the features and mode of action of various classes of target drugs. Using this method will enable selecting a medicinal product for the patient based on the analysis of objective individual changes occurred in the pathological tissue.
The embodiment of the invention discloses a novel electronic medical record sharing method fusing a block chain and real behavior characteristics, wherein a novel storage mechanism combining the block chain and a traditional database is used for replacing the traditional medical record; medical record data is converted into a hash index and stored in the block chain, so that the load of the block chain is reduced. The function of deleting blocks earlier in time in the blockchain and archiving them in the database. And the patient registration module is used for generating a unique public key and a unique private key corresponding to the patient for the patient. An innovative block packing mechanism is used for solving the problem that the system works too busy in the daytime and is too idle at night. A hospital node medical record data request mechanism based on intelligent contracts is used for a certain hospital node to request patient resume data from other hospital nodes. The method is mainly applied to the fields of medical data sharing among hospitals, medical block chain data analysis and the like, and has certain safety while realizing sharing.
The purpose of this Phase III, randomized, double-blinded, placebo-controlled, multi-center study is to evaluate the immunogenicity, safety, and tolerability of CSL Limited Inactivated Influenza Vaccine in adults ages 18 to less than 65. The primary objective of this study is to demonstrate that vaccination with CSL Limited Inactivated Influenza Vaccine produces an immune response sufficient to meet the Committee for Medicinal Products for Human Use (CHMP) criteria for young adults of 40% serorconversion and 70% seroprotection. Secondary objectives are to: demonstrate clinical consistency between 3 lots (batches) of CSL Limited Inactivated Influenza Vaccine multi-dose vial presentation (Thimerosal containing); to demonstrate clinical consistency between CSL Limited Inactivated Influenza Vaccine multi-dose vial presentation (Thimerosal containing) and CSL Limited Inactivated Influenza Vaccine pre-filled syringe presentation (Thimerosal-free); and to demonstrate acceptable safety and tolerability of CSL Limited Inactivated Influenza Vaccine multi-dose vial presentation (Thimerosal containing) and pre-filled syringe presentation (Thimerosal-free). Primary endpoints are seroprotection rate and seroconversion rate. Seroprotection is defined as a minimum post-vaccination humagglutination inhibition (HI) titer of 1:40, and seroconversion is defined as an increase in HI antibody titer of at least 4-fold, with a minimum post-vaccination HI titer of 1:40. Secondary endpoints are: comparison of the Geometric Mean Titers to influenza hemagglutinin antigens post vaccination of the active treatment arms; and the number and rate of the type, frequency and intensity of adverse events (AE) in the active treatment arms. Approximately 1250 (and up to 1359) healthy adults, ages 18 to less than 65 years old, will be enrolled into this clinical trial. Subjects who meet the inclusion criteria for the study will be randomized in a 1:1:1:1:1 ratio to receive 1 of 3 lots of vaccine in multidose vials, a single lot of vaccine in pre-filled syringes or placebo in multi-dose vials (250 subjects per group). Vaccine will be prepared and administered by an unblinded vaccine administrator, who will not be involved in subsequent assessments. Subjects will be observed in the clinic for at least 30 minutes after vaccination, and subjects will maintain a 5-day, post-vaccination solicited AE and local reaction memory aid and a 21-day unsolicited AE memory aid. Subjects will return to the clinic at day 5 to review their reactogenicity memory aid. Subjects will also return to clinic on Day-21 post-vaccination for AE and concomitant medication assessment, a targeted physical examination (if indicated), and a review of the memory aid. Serum for antibody titers will be drawn prior to vaccination and on Day-21 post-vaccination. Subjects will participate for up to 24 days.
A nurse-administered intervention, which includes a behavioral and a medication management component. The intervention consists of very brief monthly telephone calls and occurs over 12 months. Upon request, participants may also be mailed additional supportive educational material to supplement phone intervention. They will also receive a letter clarifying medications reviewed with them during the nurse-administered intervention.
A water-miscible solid product in tablet, pellet, sheet, stick, or powder form, convertible into a jelly, cream or lotion by the addition of hot water is produced by saponifying a soap-forming acid, e.g. higher fatty, resin or napthenic acid, with a hydroxide of an alkali metal or of an organic base, in the presence of up to 10 per cent by weight of the mixture of a non-soap-forming organic acid, e.g. citric or acetic acid, incorporating a wax before or after saponification, heating to remove water and allowing the product to solidify on cooling.  Additional surface tension decreasing agents, e.g. alcohols or phenols and glycerol, is or are incorporated prior to the solidification of the mixture, e.g. in the initial mixture but if the agent is volatile it is added after the cooling of the saponified mixture.  Medicaments, scents, preservatives, emollients, colouring materials, or mixtures thereof may be incorporated in the mixture after saponification but prior to solidification.
PURPOSE:To substantially reduce the water content, to easily produce a high- quality dehydrated article without deteriorating the quality and to stably maintain the servie life of the commercial products over a long period by using a dehydrating agent with anhydrous trehalose as the effective component. CONSTITUTION:This dehydrating agent contains anhydrous trehalose as the essential component. A material contg. water is efficiently dehydrated by this agent, moreover the dehydrated article is extremely stable, hence the agent is widely used. Namely, the anhydrous trehalose is incorporated into the water- contg. food, medicine, etc., and converted to hydrous trehalose crystal, hence a large amt. of water is collected by the anhydrous trehalose. Since the anhydrous trehalose acts as an extremely effective dehydrating agent and is widely used even for an acidic water-contg. material, high-quality dehydrated food, high-activity stable dehydrated medicine, etc., are easily produced.